Safety and efficacy of fimasartan in patients with arterial hypertension (Safe-KanArb study): An open-label observational study

American Journal of Cardiovascular Drugs

Volumn 13, Issue 1, 2013, Pages 47-56

  Park, Jeong Bae ^a   Sung, Ki Chul ^b   Kang, Seok Min ^c   Cho, Eun Joo ^d  

^a Kwandong University College of Medicine   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

^d The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

FIMASARTAN;

ABDOMINAL PAIN; ACNE; ACROPARESTHESIA; ADULT; ANGINA PECTORIS; ANKLE EDEMA; ANOREXIA; ARTICLE; ASTHMA; BACKACHE; BITTER TASTE; BLEEDING; BLURRED VISION; CHLOASMA; CONSTIPATION; COUGHING; DELIRIUM; DIABETES MELLITUS; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; ERECTILE DYSFUNCTION; FACE EDEMA; FATIGUE; FEMALE; HEADACHE; HEART PALPITATION; HEARTBURN; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMOBILIZATION; MAJOR CLINICAL STUDY; MALE; MENSTRUAL IRREGULARITY; NAUSEA; OBESITY; OBSERVATIONAL STUDY; OPEN STUDY; PAIN; PARESTHESIA; PATIENT COMPLIANCE; PERIODONTAL DISEASE; PHLEBITIS; PHOTOPHOBIA; PRIORITY JOURNAL; PRURITUS; PULSE RATE; RISK FACTOR; SIDE EFFECT; SLEEP DISORDER; SMOKING; STIFF NECK; STOMATITIS; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TEMPOROMANDIBULAR PAIN; THORAX PAIN; TINNITUS; TOENAIL HEMORRHAGE; TREATMENT DURATION; UNCONSCIOUSNESS; VARICOSIS; VISUAL DISORDER; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

ADULT; AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; BLOOD PRESSURE; DIZZINESS; FEMALE; HEADACHE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PYRIMIDINES; TETRAZOLES; TREATMENT OUTCOME;

EID: 84874078595     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.1007/s40256-013-0004-9     Document Type: Article

References (33)

1. Wassmann S, Nickenig G. The role of the AT1 receptor in the cardiovascular continuum. Eur Heart J. 2004;6(Suppl H):H3-9.
2. Aulakh GK, Sodhi RK, Singh M. An update on non-peptide angiotensin receptor antagonists and related RAAS modulators. Life Sci. 2007;81(8):615-39.
3. Gavras H, Flessas A, Ryan TJ, et al. Angiotensin II inhibition: treatment of congestive cardiac failure in a high-renin hypertension. JAMA. 1977;238:880-92.
4. Choi DJ, Han S, Jeon ES, et al. Characteristics, outcomes and predictors of long-term mortality for patients hospitalized for acute heart failure: a report from the Korean heart failure registry. Korean Circ J. 2011;41(7):363-71.
5. Sawada T, Yamada H, Dahlöf B, et al. on Kyoto Heart Study Group. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: Kyoto Heart Study. Eur Heart J. 2009;30(20):2461-9.
6. Mochizuki S, Dahlöf B, Shimizu M, et al. on Jikei Heart Study Group. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet. 2007;369(9571):1431-9.
7. Mancia G, De Backer G, Dominiczak A, et al. Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105-87.
8. Ogihara T, Kikuchi K, Matsuoka H, et al. Japanese Society of Hypertension committee. The Japanese society of hypertension guidelines for the management of hypertension (JSH 2009). Hypertens Res. 2009;32(1):3-107.
9. The Seventh Report of Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289:2560-72.
10. Wexler RR, Greenlee WJ, Irvin JD, et al. Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy. J Med Chem. 1996;39:625-56.
11. Zannad F, Fay R. Blood pressure-lowering efficacy of olmesartan relative to other angiotensin II receptor antagonists: an overview of randomized controlled studies. Fundam Clin Pharmacol. 2007;21(2):181-90.
12. White WB, Weber MA, Sica D, et al. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension. 2011;57(3):413-20.
13. Nagel JM, Tietz AB, Göke B, et al. The effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjects. Metabolism. 2006;55(9):1149-54.
14. Sica DA, Schoolwerth AC. Part 1. Uric acid and losartan. Curr Opin Nephrol Hypertens. 2002;11(5):475-82.
15. Yi S, Kim TE, Yoon SH, et al. Pharmacokinetic interaction of fimasartan, a new angiotensin II receptor antagonist, with amlodipine in healthy volunteers. J Cardiovasc Pharmacol. 2011;57:682-9.
16. Kim TW, Yoo BW, Lee JK, Kim JH, Lee KT, Chi YH, Lee JY. Synthesis and antihypertensive activity of pyrimidin-4(3H)-one derivatives as losartan analogue for new angiotensin II receptor type 1 (AT1) antagonists. Bioorg Med Chem Lett. 2012;22(4):1649-54.
17. Lee SE, Kim YJ, Lee HY, et al. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): A 12-week, Phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension. Clin Ther. 2012;34(3):552-68.
18. Basile J. Blood pressure responder rates versus goal rates: which metric matters? Ther Adv Cardiovasc Dis. 2009;3(2):157-74.
19. Yusuf S, Teo K, Anderson C, on Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial. Lancet. 2008;372:1174-83.
20. McIntyre M, Coffe SE, Michalok RA, et al. Losartan, an orally active angiotensin (AT1) receptor antagonist: a review of its efficacy and safety in essential hypertension. Pharmacol Ther. 1997;74(2):181-94.
21. McClellan JK, Goa KL. Candesartan cilexetil: a review of its use in essential hypertensions. Drugs. 1998;56(5):847-69.
22. Gillis JC, Merkham A. Irbesartan: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension. Drugs. 1997;54(6):885-902.
23. Sica D, White WB, Weber MA, et al. Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich). 2011;13:467-72.
24. Haymore BR, Yoon J, Mikita CP, et al. Risk of angioedema with angiotensin receptor blockers in patients with prior angioedema associated with angiotensin-converting enzyme inhibitors: a metaanalysis. Ann Allergy Asthma Immunol. 2008;101:495-9.
25. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-59.
26. Sica DA, Black HR. Current concepts of pharmacotherapy in hypertension: ACE inhibitor-related angioedema: can angiotensin-receptor blockers be safely used? J Clin Hypertens (Greenwich). 2002;4:375-80.
27. Oparil S, Williams D, Chrysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens. 2001;3:283-91.
28. Neutel JM, Smith DHG. Evaluation of angiotensin II receptor blockers for 24-hour blood pressure control: Meta-analysis of a clinical database. J Clin Hypertens. 2003;1:58-63.
29. Center for Drug Evaluation and Research Medical Review(s). NDA: 200796 Azilsartan medoxomil (Edarbi) for hypertension [online]. http://www.accessdata. fda.gov/drugsatfda-docs/nda/2011/200796Orig1s000MedR.pdf.
30. Blankestijn PJ, Rupp H. Clinical profile of eprosartan: a different angiotensin II receptor blocker. Cardiovasc Hematol Agents Med Chem. 2008;6(4):253-7.
31. Wogen J, Kreilick CA, Livornese RC, et al. Patient adherence with amlodipine, lisinopril, or valsartan therapy in a usual-care setting. J Manag Care Pharm. 2003;9(5):424-9.
32. Vegter S, Nguyen NH, Visser ST, et al. Compliance, persistence, and switching patterns for ACE inhibitors and ARBs. Am J Manag Care. 2011;17(9):609-16.
33. Enlund H. Measuring patient compliance in antihypertensive therapy - some methodological aspects. J Clin Hosp Pharm. 1982;7(1):43-51.